Electromed, Inc.
ELMD Healthcare Medical Devices
Electromed, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $73.8 million, up 15.3% from fiscal 2025. In the quarter to June 2026, revenue grew 11.6%, EPS grew 57.7% and free cash flow fell 25.2%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
Follow ELMD
Electromed, Inc. (ELMD) Piotroski F-score
Electromed, Inc.'s Piotroski F-score for fiscal 2026 is 8 out of 9: 8 of nine tests of profitability, leverage and efficiency passed, unchanged from fiscal 2025.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2026 | 8 | 0.00 |
| FY2025 | 8 | 0.00 |
| FY2024 | 8 | 1.00 |
| FY2023 | 7 | 3.00 |
| FY2022 | 4 | 0.00 |
| FY2021 | 4 | (3.00) |
| FY2020 | 7 | 2.00 |
| FY2019 | 5 | 1.00 |
| FY2018 | 4 | (1.00) |
| FY2017 | 5 | — |
How fiscal 2026’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 18.82% | 14.22% | Pass | 1 |
| Positive operating cash flow | 9.67m | 11.39m | Pass | 1 |
| Rising return on assets | 18.82% | 14.22% | Pass | 1 |
| Cash flow above net income | (1.64m) | 3.86m | Fail | 0 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 4.69 | 4.31 | Pass | 1 |
| No new shares issued | 8,266,000 | 8,454,000 | Pass | 1 |
| Rising gross margin | 78.54% | 78.08% | Pass | 1 |
| Rising asset turnover | 1.23 | 1.21 | Pass | 1 |
| Piotroski F-score | Strong — most fundamentals improved | 8 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| INFU InfuSystems Holdings, Inc. compare | 8 |
| ELMD Electromed, Inc. | 8 |
| LAB Standard BioTools Inc. compare | 4 |
| CATX Perspective Therapeutics, Inc. compare | 3 |
| TLSI TriSalus Life Sciences, Inc. compare | 3 |
| RXST RxSight, Inc. compare | 3 |
| TMCI Treace Medical Concepts, Inc. compare | 2 |
| QSI Quantum-Si Incorporated compare | 2 |
| PROF Profound Medical compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover